Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 39Carcinoma, Renal Cell 28Carcinoma, Hepatocellular 18Neoplasm Metastasis 16Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Lung Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

pembrolizumab 5fludarabine 2enfortumab vedotin 2darolutamide 2atezolizumab 2aldesleukin 2Riluzole 2Nivolumab 2Mitomycin 2Fecal Microbiota Transplantation 2Cyclophosphamide 2vedolizumab 1relatlimab 1prednylidene 1olaparib 1lenvatinib 1deltacortene 1cabozantinib 1Watchful Waiting 1Transurethral Resection of Prostate 1Tadalafil 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Rivaroxaban 1Radiosurgery 1Radiation Dose Hypofractionation 1Pregnancy Tests 1Prednisone 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Urogenital Neoplasms × Nivolumab × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT06237920 2025-09-03

TURANDORELA

The Netherlands Cancer Institute

Phase 2 Recruiting
90 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡